🇺🇸 FDA
Patent

US 10213445

Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer

granted A61KA61K31/138A61K31/655

Quick answer

US patent 10213445 (Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/138, A61K31/655, A61K47/54, A61K47/542